Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

ClinicalTrials.gov ID: NCT02503332

Public ClinicalTrials.gov record NCT02503332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients With Geographic Atrophy (GA)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).

Study identification

NCT ID
NCT02503332
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Enrollment
246 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 23, 2015
Primary completion
Jul 13, 2017
Completion
Jan 16, 2018
Last update posted
Oct 5, 2020

2015 – 2018

United States locations

U.S. sites
35
U.S. states
21
U.S. cities
34
Facility City State ZIP Site status
Retina Speciality Institute Mobile Alabama 36606
Retinal Research Institute Phoenix Arizona 85014
Retina Vitreous Asociates Mdical Goup Beverly Hills California 90211
The Gavin Herbert Eye Institute/UC Irvine Irvine California 92697
University of Southern California - USC Eye Institute Los Angeles California 90033
Byers Eye Institute at Stanford, Stanford School of Medicine Palo Alto California 94303
New England Retina Associates New London Connecticut 06320
Florida Eye Microsurgical Institute, Inc. Boynton Beach Florida 33426
Retina Health Center Fort Myers Florida 33907
Bascom Palmer Eye Institute Miami Florida 33136
South East Retina Augusta Georgia 30909
Illinois Retina Associates Harvey Illinois 60426
Midwest Eye Institute Indianapolis Indiana 46290
Elman Research Baltimore Maryland 21237
Ophthalmic Consultants of Boston Boston Massachusetts 02114
Associated Retinal Consultants PC Grand Rapids Michigan 45946
Associated Retinal Consultants, PC Traverse City Michigan 49586
Mayo Clinic Rochester Minnesota 55905
Eyesight Opthalmic Services PA Portsmouth New Hampshire 03801
Vitreous Retina Macula Consultants of New York New York New York 10022
Charlotte Eye Ear Nose and Throat Associates Charlotte North Carolina 28210
Duke University, Duke Eye Center Durham North Carolina 27705
Charlotte Eye Ear Nose and Throat Associates Statesville North Carolina 28677
Cleveland Clinic Foundation/ Cole Eye Institute Cleveland Ohio 44106
Retina Associates of Cleveland Cleveland Ohio 44122
Mid Atlantic Philadelphia Pennsylvania 19006
Black Hills Regional Eye Institute Rapid City South Dakota 57701
Tennessee Retina, PC Nashville Tennessee 37203
Retina Research Institute of Texas Abilene Texas 79606
Retina Research Center Austin Texas 78705
Retina Consultants of Houston Houston Texas 77030
Valley Retina Institute, PA McAllen Texas 75803
Retina Specialists Plano Texas 75093
Retina Consultants of Houston (The Woodlands) The Woodlands Texas 77384
University of Utah Salt Lake City Utah 84132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02503332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 5, 2020 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02503332 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →